Opioids have been the source of much controversy since the first documented use of opium, from the poppy Papaver somniferum, over 5000 years ago, which was described as Hul Gil or the 'joy plant'. Over the centuries they have been used for almost all medical conditions, some with better outcomes than others, although it was not long before their euphoric effects were discovered and opioids became drugs of misuse.
More recently, opioids have been used as effective analgesics for the relief of acute pain and in palliative care, but their use in persistent non-cancer pain has been more controversial. Although some clinical studies have demonstrated short-term benefit, there has been a massive increase in the prescribing of strong opioids despite a lack of evidence for long-term effectiveness. Recent epidemiological studies from North America have suggested that both abuse and mortality associated with prescription opioids have increased alarmingly.
In this first themed edition of the British Journal of Pain there is an update on opioid pharmacology for the busy clinician and several papers addressing topical issues regarding contemporary opioid use, including opioid-induced endocrine dysfunction and neuraxial opioid delivery for both cancer and non-cancer indications. To add an international perspective, there is a paper outlining strategies used to minimise addiction in North America. Also included are short commentaries on the confusing subject of opioid equivalences and why opioid prescribing has become prominent on both public health and political agendas, together with a short summary of the British Pain Society's statement, Opioids for Persistent Pain: Good Practice (2010).
Without desiring the imposition of legislative changes or tightened restrictions on opioid availability, it is imperative to show that opioids provide demonstrable benefit and improved outcomes for the patients to whom they are prescribed, and the pain management community must set the example for other healthcare professionals.
